TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Sirius JV will be owned 51% by Sirius and 49% by Adani
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Marks remarkable acceleration in innovation using AI technology
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Subscribe To Our Newsletter & Stay Updated
